

## Managing common infections NICE guideline committee meeting 1

**Date:** 21/12/2016

**Location:** National Institute for Health and Care Excellence, Level 1A, City Tower, Piccadilly Plaza, Manchester, M1 4BT

**Minutes:** Final

<b>Committee members present:</b>	
Tessa Lewis – Chair (TL)	Present for notes 1 – 12
Jan Alford (JA)	Present for notes 1 – 12
Kieran Hand (KH)	Present for notes 1 – 12
Alastair Hay (AH)	Present for notes 4 – 11
Peter Jenks (PJ)	Present for notes 1 – 12
Clodna McNulty (CM)	Present for notes 4 – 11
Mitul Patel (MP)	Present for notes 1 – 12
Carole Pitkeathley (CP)	Present for notes 1 – 12
Avril Tucker (AT)	Present for notes 1 – 12
Caroline Ward (CW)	Present for notes 1 – 12

<b>In attendance:</b>	
Ruth Garnett (RG)	Present for notes 1 – 12
Johanna Hulme (JH)	Present for notes 1 – 12
Chloe Kastoryano (CK)	Present for notes 1 – 12
Jon Littler (JL)	Present for note 4
Greg Moran (GM)	Present for notes 1 – 12
Caroline Mulvihill (CMu)	Present for notes 1 – 12
Ian Pye (IP)	Present for notes 1 – 12
Amanda Upton (AU)	Present for notes 1 – 12
Liz Watson (LW)	Present for notes 1 – 12

<b>Observers:</b>	
Albany Meikle	Present for notes 10 – 12
Rachel Walsh	Present for notes 10 – 12

## **1. Welcome, introductions and apologies**

The Chair welcomed the Committee members and attendees to the 1<sup>st</sup> public health advisory committee 4 (PHAC 4) meeting on managing common infections.

TL suggested leaving the introductions until all committee members were present. Following the arrival of AH and CM the Committee members and attendees introduced themselves.

The Chair outlined the objectives of the meeting, which included:

- an overview of NICE policies and procedures relevant to the work of the committee
- agreeing the review questions and protocols.

## **2. Overview of NICE**

JH presented an overview of NICE.

## **3. Patient and carer involvement in guideline development**

CK presented an overview of the NICE public involvement programme.

10.15 AH and JL arrived.

## **4. Meetings in public**

10.17 CM arrived.

JL presented an overview of NICE meetings held in public.

JL left the meeting

## **5. NICE policies and committee role and responsibilities including declarations of interest**

IP gave a presentation on the following areas that are relevant to the committee:

- Confidentiality
- Declaring and dealing with conflicts of interest
- Social value judgements
- NICE equalities scheme
- Travel and subsistence policy (non-staff)

IP asked the committee to declare any relevant interests.

Name	Job title, organisation	Declarations of Interest, date declared
Kieran Hand	Consultant Pharmacist – Anti-Infectives Pharmacy Department, University Hospital Southampton NHS Foundation Trust	<p>Personal financial interests</p> <p>Speaker honoraria from Merck Sharp &amp; Dohme pharmaceuticals</p> <p>Advisory board honoraria from Pfizer pharmaceuticals, Merck Sharp &amp; Dohme pharmaceuticals</p> <p>Non-personal financial interests</p> <p>Royalty contract between employer NHS Foundation Trust and software developer Horizon Strategic Partners with respect to MicroGuide smartphone application for antimicrobial guidelines (decision-support module only)</p> <p>Research funding contract between employer NHS Foundation Trust and Merck Sharp &amp; Dohme Pharmaceuticals for study of current management of complicated skin and skin structure infection in hospitals</p> <p>Sponsorship from Astellas Pharma of employer NHS Foundation Trust promotional activities around European Antibiotic Awareness Day</p> <p>Personal non-financial interests</p> <p>Member of Department of Health scientific advisory committee for antimicrobial resistance and healthcare-associated infection (ARHAI)</p> <p>Member of Council at British Society for Antimicrobial Chemotherapy</p> <p>Member of antimicrobial expert advisory group of Royal Pharmaceutical Society</p> <p>Member of UK Clinical Pharmacy Association's Pharmacy Infection Network</p> <p>Member of the Guild of Healthcare Pharmacists within Unite Union</p>
Professor Alastair Hay	Academic - Professor of Primary Care, University of Bristol Clinical - Part time salaried GP, The Concord Medical Centre, Bristol, UK	<p>I have no financial conflicts to declare.</p> <p>As a University academic who has published extensively in the field, I could be perceived as having an interest in seeing my work cited in the NICE guideline. However, my primary interest is to promote the safe, effective and judicious use of antibiotics in order to preserve their effectiveness for future generations. –</p>
Peter Jenks	Consultant Microbiologist and Director of Infection Prevention and Control, Plymouth Hospitals NHS Trust	I am a Director of Plymouth Infection Consultancy, a limited company that provides private microbiology advice to local providers.

Clidna McNulty	Head of Primary Care Unit, Public Health England	<p>Observer on BSAC Council.</p> <p>Member of ARHAI and ESPAUR.</p> <p>Member of NICE Antimicrobial stewardship Guideline Development Group.</p> <p>CM has spoken at antimicrobial resistance symposiums sponsored by public bodies, and one by bioMerieux but received no payment.</p> <p>She leads the development of national Public Health England antibiotic and lab use guidance for GPs which covers the diagnosis and treatment of infections.</p> <p>She has received grants from several publically funded research bodies.</p> <p>CM was the lead in the development of TARGET and promotes the TARGET resources hosted by the RCGP.</p>
Mitul Patel	<p>Consultant Microbiologist and Clinical Lead (Microbiology)</p> <p>Birmingham Children's Hospital NHS Trust and Consultant Microbiologist</p> <p>Birmingham Women's Hospital NHS Trust</p>	<p>Biofire/Biomerieux: Received assistance with travel, attended annual general meeting, received honorarium for lecture</p> <p>Pfizer: Member of advisory board for tigecyclin, attended meetings, received assistance with travel and honorarium for lecture</p> <p>MSD: Received honorarium for lecture</p>
Carole Pitkeathley	Lay Member	<p>I have no interests as described in the policy. Currently I am involved in the following:</p> <p>Chair Marine Medical Group Patient Participation Group</p> <p>Board Member Healthwatch Northumberland</p> <p>Trustee Age UK North Tyneside</p> <p>Non-Exec Director/Charity Rep – Life Choices Plus (T/A EveryDay) a wholly owned subsidiary of Age UK North Tyneside</p> <p>Trustee NEA</p> <p>All the above are unpaid and do not represent a conflict of interest</p>

The Chair and a senior member of the Developer's team noted that the interests declared did not prevent the attendees from fully participating in the meeting.

## 6. Guideline development process

JH gave a presentation on the guideline development process.

<b>7. Guideline scope</b>
JH gave a presentation on the scope of the guideline.
<b>8. Presentation of the final guideline</b>
JH gave a presentation on the proposed presentation of the final guideline. JH provided clarification in response to questions from the committee. The committee discussed the proposed final presentation of the guideline. JH asked the committee to consider what they thought the most effective presentation of the final guideline would be and feed it back to the NICE team in the New Year.
<b>9. Introduction to review protocols</b>
GM gave a presentation on the format and purpose of review protocols.
<b>10. Review protocols</b>
GM gave a presentation on the review protocol for acute rhinosinusitis (or sinusitis). Following discussion, the committee agreed the review protocol as amended by JH including critical and important outcomes.
GM gave a presentation on the review protocol for acute sore throat. Following discussion the committee agreed the review protocol as amended by JH including critical and important outcomes.
The committee agreed to review and agree the otitis media review protocol via email.
<b>11. Summary and next steps</b>
JH gave a presentation on the next steps in the development process.
15.45 AH and CM left the meeting.
<b>12. Any other business</b>
No additional items were raised. The meeting closed at 15.55

**Date of next meeting:** Tuesday 14 February 2017, 10.00 – 16.00

**Location of next meeting:** National Institute for Health and Care Excellence,  
Level 1A, City Tower, Piccadilly Plaza, Manchester,  
M1 4BT